These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 26818083)

  • 1. Non-prescribed use of opioid substitution medication: Patterns and trends in sub-populations of opioid users in Germany.
    Schulte B; Schmidt CS; Strada L; Götzke C; Hiller P; Fischer B; Reimer J
    Int J Drug Policy; 2016 Mar; 29():57-65. PubMed ID: 26818083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
    Johnson B; Richert T
    Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
    Larance B; Lintzeris N; Ali R; Dietze P; Mattick R; Jenkinson R; White N; Degenhardt L
    Drug Alcohol Depend; 2014 Mar; 136():21-7. PubMed ID: 24461476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors.
    Johnson B; Richert T
    Int J Drug Policy; 2015 Feb; 26(2):183-90. PubMed ID: 25465344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
    Winstock AR; Lea T; Sheridan J
    Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-prescribed use of substitution medication among German drug users--prevalence, motives and availability.
    Schmidt CS; Schulte B; Wickert C; Thane K; Kuhn S; Verthein U; Reimer J
    Int J Drug Policy; 2013 Nov; 24(6):e111-4. PubMed ID: 23726899
    [No Abstract]   [Full Text] [Related]  

  • 7. Illicit use of opioid substitution drugs: prevalence, user characteristics, and the association with non-fatal overdoses.
    Bretteville-Jensen AL; Lillehagen M; Gjersing L; Andreas JB
    Drug Alcohol Depend; 2015 Feb; 147():89-96. PubMed ID: 25543167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden.
    Richert T; Johnson B
    Harm Reduct J; 2015 Feb; 12():1. PubMed ID: 25889208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment.
    Haber PS; Elsayed M; Espinoza D; Lintzeris N; Veillard AS; Hallinan R
    Drug Alcohol Depend; 2017 Dec; 181():132-139. PubMed ID: 29054032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diversion of methadone and buprenorphine from opioid substitution treatment: the importance of patients' attitudes and norms.
    Johnson B; Richert T
    J Subst Abuse Treat; 2015 Jul; 54():50-5. PubMed ID: 25744650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diversion of methadone and buprenorphine from opioid substitution treatment: patients who regularly sell or share their medication.
    Johnson B; Richert T
    J Addict Dis; 2015; 34(1):1-17. PubMed ID: 25496247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.
    Larance B; Degenhardt L; Lintzeris N; Bell J; Winstock A; Dietze P; Mattick R; Ali R; Horyniak D
    Drug Alcohol Depend; 2011 Nov; 118(2-3):265-73. PubMed ID: 21565452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
    Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
    Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia.
    Winstock AR; Lea T
    Subst Use Misuse; 2010; 45(1-2):240-52. PubMed ID: 20025451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective.
    Johnson B; Richert T
    J Psychoactive Drugs; 2014; 46(5):427-35. PubMed ID: 25364995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls.
    Rapeli P; Fabritius C; Alho H; Salaspuro M; Wahlbeck K; Kalska H
    BMC Clin Pharmacol; 2007 Jun; 7():5. PubMed ID: 17565668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.
    Smith KE; Tillson MD; Staton M; Winston EM
    Drug Alcohol Depend; 2020 Mar; 208():107837. PubMed ID: 31951906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies.
    Betts KS; Chan G; McIlwraith F; Dietze P; Whittaker E; Burns L; Alati R
    Addiction; 2016 Jul; 111(7):1214-23. PubMed ID: 26857811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DYNAMICS OF OPIOID SUBSTITUTION TREATMENTIN DIFFERENT INITIAL SUBSTANCE USER OPIOID DEPENDENT PATIENTS.
    Todadze Kh; Mosia S
    Georgian Med News; 2016 May; (254):56-61. PubMed ID: 27348169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.
    Kenworthy J; Yi Y; Wright A; Brown J; Maria Madrigal A; Dunlop WCN
    J Med Econ; 2017 Jul; 20(7):740-748. PubMed ID: 28489467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.